Eurazeo (RF) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eurazeo (RF) has a cash flow conversion efficiency ratio of 0.012x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€79.71 Million ≈ $93.19 Million USD) by net assets (€6.49 Billion ≈ $7.59 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Eurazeo's balance sheet to measure how much of total assets are equity-financed.
Eurazeo - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Eurazeo's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Eurazeo (RF) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Eurazeo Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eurazeo ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Uxi Unicomp Technology Co. Ltd. A
SHG:688531
|
N/A |
|
AUB Group Ltd
AU:AUB
|
0.040x |
|
BSP Financial Group Ltd
AU:BFL
|
0.103x |
|
Zhejiang Orient Holdings Co Ltd
SHG:600120
|
0.049x |
|
Disc Medicine Inc.
NASDAQ:IRON
|
-0.090x |
|
Bausch Health Companies Inc
TO:BHC
|
-0.213x |
|
YAMAHA CORP.SP.ADR/1 O.N.
F:YHAA
|
N/A |
|
Co-Tech Development
TWO:8358
|
0.000x |
Annual Cash Flow Conversion Efficiency for Eurazeo (2007–2025)
The table below shows the annual cash flow conversion efficiency of Eurazeo from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see Eurazeo market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €6.49 Billion ≈ $7.59 Billion |
€125.83 Million ≈ $147.11 Million |
0.019x | +112.36% |
| 2024-12-31 | €7.55 Billion ≈ $8.82 Billion |
€68.88 Million ≈ $80.53 Million |
0.009x | +756.90% |
| 2023-12-31 | €8.35 Billion ≈ $9.77 Billion |
€-11.61 Million ≈ $-13.57 Million |
-0.001x | -105.07% |
| 2022-12-31 | €9.28 Billion ≈ $10.85 Billion |
€254.09 Million ≈ $297.06 Million |
0.027x | -27.64% |
| 2021-12-31 | €8.36 Billion ≈ $9.78 Billion |
€316.42 Million ≈ $369.93 Million |
0.038x | +62.94% |
| 2020-12-31 | €6.10 Billion ≈ $7.14 Billion |
€141.73 Million ≈ $165.70 Million |
0.023x | -67.95% |
| 2019-12-31 | €6.62 Billion ≈ $7.74 Billion |
€479.57 Million ≈ $560.67 Million |
0.072x | +87.67% |
| 2018-12-31 | €6.27 Billion ≈ $7.34 Billion |
€242.21 Million ≈ $283.16 Million |
0.039x | +17.85% |
| 2017-12-31 | €6.00 Billion ≈ $7.01 Billion |
€196.43 Million ≈ $229.65 Million |
0.033x | +24.57% |
| 2016-12-31 | €5.24 Billion ≈ $6.12 Billion |
€137.68 Million ≈ $160.96 Million |
0.026x | +139.10% |
| 2015-12-31 | €4.75 Billion ≈ $5.55 Billion |
€-319.26 Million ≈ $-373.25 Million |
-0.067x | -160.77% |
| 2014-12-31 | €3.52 Billion ≈ $4.12 Billion |
€389.80 Million ≈ $455.71 Million |
0.111x | -43.18% |
| 2013-12-31 | €3.45 Billion ≈ $4.03 Billion |
€671.06 Million ≈ $784.54 Million |
0.195x | -5.75% |
| 2012-12-31 | €3.30 Billion ≈ $3.86 Billion |
€681.69 Million ≈ $796.97 Million |
0.207x | -19.25% |
| 2011-12-31 | €3.86 Billion ≈ $4.51 Billion |
€988.08 Million ≈ $1.16 Billion |
0.256x | +58.89% |
| 2010-12-31 | €3.94 Billion ≈ $4.61 Billion |
€634.95 Million ≈ $742.32 Million |
0.161x | -42.84% |
| 2009-12-31 | €3.87 Billion ≈ $4.53 Billion |
€1.09 Billion ≈ $1.28 Billion |
0.282x | +1.11% |
| 2008-12-31 | €3.93 Billion ≈ $4.59 Billion |
€1.09 Billion ≈ $1.28 Billion |
0.279x | +124.34% |
| 2007-12-31 | €5.43 Billion ≈ $6.35 Billion |
€674.61 Million ≈ $788.69 Million |
0.124x | -- |
About Eurazeo
Eurazeo SE is a private equity and venture capital firm specializing in growth capital, series C, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in upper mid-market, mid-market and listed public companies, small- and mid-cap healthcare companies, equity in the small-mid and mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, … Read more